Rocket Pharmaceuticals, Inc. , a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that ...

William Blair analyst Sami Corwin has maintained their bullish stance on RCKT stock, giving a Buy rating yesterday. Sami Corwin has given his ...

Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The ...

This study provides convincing evidence for functional subpopulations of β-cells responsible for Ca2+ signal initiation and maintenance using novel three-dimensional light sheet microscopy imaging and ...

The growing demand for alopecia treatments is mainly driven by the rising global prevalence of alopecia, influenced by ...

About PYRUKYND® (mitapivat) PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States, and for the ...

Q3 2024 Earnings Call Transcript October 31, 2024 Operator: Good morning, and welcome to Agios’ Third Quarter 2024 Conference Call. [Operator Instructions] Please be advised that today’s call is being ...

Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty Pharma ...

When your red blood cells are broken down faster than this, it is called hemolysis. Hemolysis can be caused by many different things. Some forms you inherit, like hereditary spherocytosis and pyruvate ...

Enrollment has finished for the Phase 3 RISE UP study, which is testing the oral therapy mitapivat in people with sickle cell ...

Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today ...

Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases ...